title: On the methodology of drug trials in migraine with aura.
abstract: BACKGROUND
  Specific problems occur in clinical treatment trials for migraine with aura that differ from those encountered in treatment trials for migraine without aura.
  
  
  CONCLUSIONS
  Based on our experience with four such trials, we point to a number of possible solutions and outline areas for future inquiry. We make recommendations about subject selection; the choice, definition and assessment of outcome measures; optimal treatments in relation to aura and headache; and we provide samples of study report forms used to record occurrence of aura and headache in this population.
authors: Danish Headache Center, Department of Neurology, University of Copenhagen, Faculty of Health Sciences, Glostrup Hospital, Glostrup, Denmark. ahauge@dadlnet.dk
authors: Anne Werner
authors: AW
authors: Hauge
authors: Anders
authors: A
authors: Hougaard
authors: Jes
authors: J
authors: Olesen
mesh_terms: D001549:Benzamides / Q000627:therapeutic use*; D001578:Benzopyrans / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods*; D006801:Humans; D020325:Migraine with Aura / Q000188:drug therapy* / Q000517:prevention & control*; D020326:Migraine without Aura / Q000188:drug therapy / Q000517:prevention & control; D018579:Patient Selection; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D001578:Benzopyrans; C118706:tonabersat